ClinicalTrials.gg
RecruitingNCT07366541EFI-HFNOUpdated Oct 8, 2026

Predicting High-Flow Nasal Oxygen Failure Within 72 Hours Using a Physiology-Informed Dual-Domain Model at 30 Minutes

An observational study in Acute Respiratory Failure, Electrical Impedance Tomography (EIT) and High-Flow Nasal Oxygen Therapy, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Ruijin Hospital · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
115
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 93 studies in Respiratory Insufficiency with a site in China — 30 open to participants now, 30 under way, 1 of them phase 3. Respiratory Insufficiency · China.

Planned enrollment
25th of 36
115 · median 175
Started
2025
with 11 others
Observational
36 of 93
12 open now
Primary completion
2026-12
later than 17 of 29 live
Registered
80th of 93
by date
Lead sponsor
5 of 93
Ruijin Hospital

Among the 93 studies in Respiratory Insufficiency with a site in China, this one is the 25th largest by planned enrollment of the 36 observational ones that give a count, is one of 12 that started in 2025, is one of 36 observational ones, reaches primary completion later than 17 of the 29 other live ones, and was the 80th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

30 of the 93 studies in Respiratory Insufficiency with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Respiratory Insufficiency with a site in China, or all of them as a file.
02

Study summary

This is a single-center, ambispective observational cohort study of adults with acute hypoxemic respiratory failure (AHRF) receiving high-flow nasal oxygen (HFNO) as initial respiratory support. The study includes three stages. Stage 1 (retrospective derivation): the first 57 consecutive patients (May-September 2025) were retrospectively included to develop and lock a dual-domain logistic model using baseline EFI, baseline PaCO2, and 0-30 minute changes in respiratory rate (ΔRR) and SpO2 (ΔSpO2). Stage 2 (retrospective temporal validation): the later 58 patients (October 2025-March 2026) were retrospectively included, and the frozen model was directly applied without refitting; results of Stages 1 and 2 have been reported. Stage 3 (prospective validation): an independent prospective validation cohort is currently being enrolled, and the frozen model will be applied without refitting. The primary outcome is endotracheal intubation within 72 hours after HFNO initiation. This registration covers the complete study; the retrospective stages have been reported, and the prospective stage is ongoing.

Read the detailed description

This was a single-center, ambispective observational cohort study conducted at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, between May 2025 and March 2026, with an ongoing prospective validation stage. Adults with AHRF receiving HFNO as initial respiratory support were included. Patients with an immediate indication for endotracheal intubation, severe hemodynamic instability, marked consciousness disturbance or inability to cooperate with monitoring, or missing/inadequate EIT data were excluded. Clinical, physiological, blood gas, and EIT data were collected at baseline before HFNO and at 30 minutes after HFNO initiation. EFI was calculated from the global EIT impedance curve.

Stage 1 (retrospective derivation): the first 57 consecutive patients were included retrospectively; baseline EFI, baseline PaCO2, ΔRR, and ΔSpO2 were used to develop and lock a dual-domain logistic model.

Stage 2 (retrospective temporal validation): the later 58 patients were included retrospectively; the frozen model coefficients were directly applied without refitting. Results of Stages 1 and 2 have been reported.

Stage 3 (prospective validation): an independent multicenter prospective validation cohort is currently being enrolled. The same inclusion/exclusion criteria, 30-minute reassessment protocol, and frozen model will be applied without refitting.

The primary endpoint is endotracheal intubation within 72 hours after HFNO initiation.

The retrospective stages were approved by the Ethics Committee of Ruijin Hospital (Approval No. 2025232), and informed consent was waived. The prospective validation stage was approved by the same committee (Approval No. (2026592), and written informed consent is obtained from all prospectively enrolled participants.

03

Conditions studied

  • Acute Respiratory Failure
  • Electrical Impedance Tomography (EIT)
  • High-Flow Nasal Oxygen Therapy

Keywords

  • Acute hypoxemic respiratory failure
  • High-flow nasal oxygen
  • Electrical impedance tomography
  • EIT-derived flow index
  • Prediction model
  • Multicenter prospective validation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with acute respiratory failure receiving HFNO

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Acute hypoxemic respiratory failure (AHRF) requiring HFNO initiation
  • At least one of the following high-risk criteria: a) PaO₂/FiO₂ ≤200 mmHg or FiO₂ ≥0.40 to maintain SpO₂ ≥92%; b) Respiratory rate ≥25/min; c) APACHE II score ≥12; d) Bilateral infiltrates on chest imaging

Exclusion criteria

Exclusion Criteria:

  • Neuromuscular disease affecting spontaneous breathing
  • Pregnancy
  • to EIT (e.g., chest wall wounds, pacemaker)
  • Do-not-intubate order
  • Hypercapnic respiratory failure as primary diagnosis (PaCO₂ >50 mmHg with pH \<7.30 at baseline, unless mixed mechanism)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
115 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retrospective derivation cohort

    First 57 consecutive adults with AHRF receiving HFNO (May-September 2025); used to develop and lock the dual-domain model. Completed.

    Other: High-Flow Nasal Oxygen Therapy · Device: Electrical Impedance Tomography Monitoring

  • Retrospective temporal validation cohort

    Later 58 adults with AHRF receiving HFNO (October 2025-March 2026); frozen model applied without refitting. Completed.

    Other: High-Flow Nasal Oxygen Therapy · Device: Electrical Impedance Tomography Monitoring

  • Prospective validation cohort

    Independent adults with AHRF receiving HFNO; currently being prospectively enrolled at multiple centers. Frozen model applied without refitting. Ongoing.

    Other: High-Flow Nasal Oxygen Therapy · Device: Electrical Impedance Tomography Monitoring

Interventions

  • OtherHigh-Flow Nasal Oxygen Therapy

    Patients received HFNO as part of standard clinical care for acute hypoxemic respiratory failure. The treatment was titrated by the clinical team based on physiological parameters (SpO2, RR, ABG), aiming to maintain SpO2 ≥ 92% and reduce signs of respiratory distress.

  • DeviceElectrical Impedance Tomography Monitoring

    PulmoVista 500 EIT device (Dräger Medical, Lübeck, Germany) was used for continuous real-time monitoring of regional lung ventilation and to derive the EIT-derived flow index (EFI) at baseline and 30 minutes.

06

What researchers measure

Primary outcomes

  1. HFNO Failure (Endotracheal Intubation Within 72 Hours)

    HFNO failure was defined as endotracheal intubation within 72 hours after HFNO initiation due to refractory hypoxemia, progressive respiratory acidosis, severe respiratory distress, or hemodynamic instability. Escalation to noninvasive ventilation (NIV) without endotracheal intubation and within-tier adjustments (increasing flow or FiO2 without changing support modality) were NOT considered the primary failure event. The model is intended for reassessment at 30 minutes, but the outcome is assessed within 72 hours.Unit of Measure: Proportion of participants.

    Time frame: Within 72 hours after HFNO initiation.

Secondary outcomes

  1. Model Discrimination in Retrospective Temporal Validation

    Area under the receiver operating characteristic curve (AUC) of the frozen dual-domain model for predicting endotracheal intubation within 72 hours in the retrospective temporal validation cohort.Unit of Measure: AUC (dimensionless, 0-1).

    Time frame: Within 72 hours after HFNO initiation.

  2. Model Calibration in Retrospective Temporal Validation

    Calibration intercept and slope of the frozen dual-domain model in the retrospective temporal validation cohort. Unit of Measure: Dimensionless.

    Time frame: Within 72 hours after HFNO initiation.

  3. Model Discrimination in Prospective Validation

    AUC of the frozen dual-domain model for predicting endotracheal intubation within 72 hours in the ongoing prospective validation cohort.Unit of Measure: AUC (dimensionless, 0-1).

    Time frame: Within 72 hours after HFNO initiation.

  4. Model Calibration in Prospective Validation

    Calibration intercept and slope of the frozen dual-domain model in the ongoing prospective validation cohort. Unit of Measure: Dimensionless.

    Time frame: Within 72 hours after HFNO initiation.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 19 months is below that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Mar 2026 → Dec 2026 and completion Mar 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 26, 2026
StartActual
May 1, 2025
Primary completionEst.
Dec 31, 2026was Mar 2026
CompletionEst.
Dec 31, 2026was Mar 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Recruiting
changed Oct 8, 2026
Sites
Department of Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine is now Recruiting
Oct 8, 2026
Primary completion
Mar 31, 2026→Dec 31, 2026
Oct 8, 2026
Study completion
Mar 31, 2026→Dec 31, 2026
Oct 8, 2026
Enrollment
164 (actual)→115 (estimated)
Oct 8, 2026
Eligibility
Maximum age 90 Years→none
Oct 8, 2026
Interventions
Removed Device: Mechanical Ventilation Support·Device: High-Flow Nasal Oxygen Therapy With EIT Monitoring. Arm changed Physiological Validation Cohort→Prospective validation cohort. Arms added: Retrospective derivation cohort·Retrospective temporal validation cohort; arms removed: Derivation Cohort - HFNO Success·Derivation Cohort - HFNO Failure·Validation Cohort - HFNO Success·Validation Cohort - HFNO Failure
Oct 8, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore HFNC Failure Rate(Early Reassessment at 30 Minutes)Now HFNO Failure (Endotracheal Intubation Within 72 Hours)Time frame: within 30 minutes after HFNO initiation (with monitoring of outcomes up to hospital discharge) → Within 72 hours after HFNO initiation.
Oct 8, 2026
Secondary outcomes
4 added, 3 removed
What changed in the outcomes
  • AddedModel Discrimination in Retrospective Temporal ValidationTime frame: Within 72 hours after HFNO initiation.
  • AddedModel Calibration in Retrospective Temporal ValidationTime frame: Within 72 hours after HFNO initiation.
  • AddedModel Discrimination in Prospective ValidationTime frame: Within 72 hours after HFNO initiation.
  • AddedModel Calibration in Prospective ValidationTime frame: Within 72 hours after HFNO initiation.
  • RemovedPhysiological Validation of EFITime frame: During physiological measurements in mechanically ventilated patients (performed before the clinical HFNO cohort; within 48 hours of ICU admission)
  • RemovedPersistent Abnormality at 30 MinutesTime frame: within 30 minutes after HFNO initiation
  • RemovedDivergent Short-Term Response TrajectoriesTime frame: Baseline to 30 minutes after HFNO initiation
Oct 8, 2026
Contact
Study contact now listed: added c•••@foxmail.com · •••6066; added q•••@rjh.com.cn · •••0045. See the current contact
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Department of Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine · Shanghai, ChinaContact added c•••@foxmail.com · •••0045
Oct 8, 2026
Title
Predicting High-Flow Nasal Oxygen Failure at 30 MinutesWithin 72 Hours Using a Physiology-Informed Dual-Domain Model at 30 Minutes
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Completed→Recruiting
    Department of Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine is now Recruiting
    Primary completion Mar 31, 2026→Dec 31, 2026
    Study completion Mar 31, 2026→Dec 31, 2026
    Enrollment 164 (actual)→115 (estimated)
    Eligibility Maximum age 90 Years→none
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore HFNC Failure Rate(Early Reassessment at 30 Minutes)Now HFNO Failure (Endotracheal Intubation Within 72 Hours)Time frame: within 30 minutes after HFNO initiation (with monitoring of outcomes up to hospital discharge) → Within 72 hours after HFNO initiation.
    Secondary outcomes 4 added, 3 removed
    What changed in the outcomes
    • AddedModel Discrimination in Retrospective Temporal ValidationTime frame: Within 72 hours after HFNO initiation.
    • AddedModel Calibration in Retrospective Temporal ValidationTime frame: Within 72 hours after HFNO initiation.
    • AddedModel Discrimination in Prospective ValidationTime frame: Within 72 hours after HFNO initiation.
    • AddedModel Calibration in Prospective ValidationTime frame: Within 72 hours after HFNO initiation.
    • RemovedPhysiological Validation of EFITime frame: During physiological measurements in mechanically ventilated patients (performed before the clinical HFNO cohort; within 48 hours of ICU admission)
    • RemovedPersistent Abnormality at 30 MinutesTime frame: within 30 minutes after HFNO initiation
    • RemovedDivergent Short-Term Response TrajectoriesTime frame: Baseline to 30 minutes after HFNO initiation
    Interventions Removed Device: Mechanical Ventilation Support·Device: High-Flow Nasal Oxygen Therapy With EIT Monitoring. Arm changed Physiological Validation Cohort→Prospective validation cohort. Arms added: Retrospective derivation cohort·Retrospective temporal validation cohort; arms removed: Derivation Cohort - HFNO Success·Derivation Cohort - HFNO Failure·Validation Cohort - HFNO Success·Validation Cohort - HFNO Failure
    Contact Study contact now listed: added c•••@foxmail.com · •••6066; added q•••@rjh.com.cn · •••0045. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Department of Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine · Shanghai, ChinaContact added c•••@foxmail.com · •••0045
    Title Predicting High-Flow Nasal Oxygen Failure at 30 MinutesWithin 72 Hours Using a Physiology-Informed Dual-Domain Model at 30 Minutes
    + 6 other changes: index terms, verification date, oversight details, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07366541
Lead sponsor
Ruijin Hospital
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
May 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

rui zhang, Dr
Contact
ccmzhangrui@foxmail.com
0086-021-21666066
Hongping Qu
Contact
qhp10516@rjh.com.cn
0086-021-67340045
Hongping Qu
study chair · Department of Critical Care Medicine,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion